PDLI


Why Neos Therapeutics Inc (NEOS) Shares Climbed 37% Today

Neos Therapeutics Inc (NASDAQ:NEOS) is a mover and shaker out on the Street today, with investors sparking the stock on an almost 37% upturn. …

Company Update (NASDAQ:PDLI): Here’s Why PDL BioPharma Inc Shares Are Slumping 15% Today

PDL BioPharma Inc (NASDAQ:PDLI) are having a rough day, after the drug maker announced the closing of its previously announced offering of convertible …

Company Update (NASDAQ:ARIA): Ariad Pharmaceuticals, Inc. to Receive up to $200 Million Through Iclusig Non-Dilutive Synthetic-Royalty Financing with PDL BioPharma Inc

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) announced that it will receive $100 million in cash – $50 million upon deal execution late yesterday and an additional …

Stock Update (NASDAQ:PDLI): PDL BioPharma Inc Appoints Steffen Pietzke as Controller and Chief Accounting Officer

PDL BioPharma Inc (NASDAQ:PDLI) announced that the company has appointed Steffen Pietzke, CPA, to the position of controller and chief accounting officer. Mr.

Company Update (NASDAQ:PDLI): PDL BioPharma Inc Announces First Quarter 2015 Financial Results

PDL BioPharma Inc (NASDAQ:PDLI) reported financial results for the first quarter ended March 31, 2015. Total revenues for the first quarter of 2015 increased nine …

Stock Update (NASDAQ:PDLI): PDL BioPharma Announces Conversion Rate Adjustment for Convertible Note

PDL BioPharma, Inc. (NASDAQ:PDLI) today announced that the adjusted conversion rate for the 3.

Company Update (NASDAQ:PDLI): PDL BioPharma Announces Dismissal of Third and Final Shareholder Lawsuit

PDL BioPharma, Inc. (PDL or the Company) (NASDAQ:PDLI) announced that the third of three shareholder lawsuits filed in the fall of 2014, was voluntarily …

Janney Capital Remains Neutral On PDL Biopharma Following The Resign Of Ernst & Young

In a research note released today, Janney Capital analyst Kimberly Lee maintained a Neutral rating on PDL Biopharma (PDLI) with a $7 fair value, following the reporting that the …

Janney Capital Maintains Neutral On PDL Biopharma; $8 PT

In a research note released today, Janney Capital analyst Kimberly Lee maintained a Neutral rating on PDL Biopharma (PDLI) with a $8 price target, ahead of the upcoming …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts